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Stem cells and regenerative medicine: scientific,  
political and social aspects
IntroductIon
Stem cell research represents a possibility of cell and tissue renewal, damaged by serious diseases or accidents. There are countless pos-
sibilities for applying regenerative medicine using stem cells; damaged 
cartilage and bone replacement, acceleration of wound healing and skin 
renewal, heart muscle replacement after myocardial infarction and treat-
ment of neurodegenerative disorders including Parkinson’s, are only 
some of them. Next to personalized medicine and nanomedicine, regen-
erative medicine is one of the most propulsive areas of future medicine 
(1, 2, 3). Research in that field has started to develop in the last decade 
of last century and has intensified over the past 20 years. EU Commis-
sion has accepted in 2008 the proposition for the Directive of the Euro-
pean Parliament as well as Council on Standards of quality and safety of 
human organs, mainly with the purpose of transplantation. Nowadays, 
transplantation is the only possible therapy for certain terminal organ 
insufficiencies such as liver, kidney and bone marrow.
Increase in the number of chronic patients related to population aging 
has caused an increased need for transplants which seem to be fewer in 
number. In fact, there is a decrease in the number of potential donors. 
For many patients transplantation is the only possible way of treatment 
and can be lifesaving. Therefore, the need for a bigger number of trans-
plantations and alternative forms of treatment is clear. It seems that re-
generative medicine, or stem cell application, is the real alternative.
In 2001 at the EU parliament in Brussels, a meeting was held on the 
topic of „Stem cells: for the freedom of research in Europe“, where one 
of the authors of this article was invited as an expert. The meeting was 
organized by a Transnational Radical Party, instigated by patients suf-
fering from serious illnesses (4). The meeting discussed cloning and so 
called therapy cloning as well as the application of nuclear transfer 
method with the purpose of treatment. It took 8 years for Food and 
Drug Administration to approve the first clinical trial using therapy 
founded on applying embryonic stem cells for the treatment of patients 
suffering from acute bone marrow injuries. In „Human stem cell re-
search and regenerative medicine“, published by the European Science 
Foundation in 2010, it is noted that regenerative medicine probably has 
the highest chances in the renewal of bone and cartilage (5). A plausible 
explanation is reduced complexity and good accessibility of those tissues 
compared with myocardia and neuronal tissue. One should mention 
that there is large competition in the field of research and new tissue 
renewal biomaterials.
The development and fate of stem cell research is heavily influenced 
by the ethical surrounding in which that research is being conducted. 
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In 2002 European Science Foundation reported on stem 
cells, a harmonized approach of various national EU gov-
ernments was suggested to find the ways of using adult 
stem cells for future therapy, which will be acceptable to 
all interested parties and to the general population (6).
Legislation across Europe is different. Twenty five 
countries have adopted legislation which explicitly pro-
hibits human reproductive cloning (excluding Poland, 
Lithuania, Croatia, Ireland and Luxembourg). Seven 
countries allow human embryonic stem cell (hESC) re-
search and the derivation of new hESC clones from su-
pernumerary IVF embryos by low (Belgium, Sweden, 
UK, Spain, Finland, Czech Republic, Portugal). The 
same countries allow stem cell nuclear transfer by low 
except Finland, Czech Republic and Portugal who neither 
prohibit nor allow it. Three countries have adopted legis-
lation to allow the creation of embryos for research pur-
poses under strict conditions (Belgium, Sweden, UK). 
Seventeen countries allow the procurement of stem cells 
from supernumerary embryos. Six countries have not ad-
opted legislation regarding human stem cell research 
(Bulgaria, Croatia, Cyprus, Luxembourg, Romania and 
Turkey). Differing legislation may lead to differences and 
imbalanced access in Europe to treatments deriving from 
hESC research. Patients may travel from one country to 
another where they may have access to a treatment that is 
forbidden in their own country leading to unequal distri-
bution of benefits and burdens of stem cell research. Cer-
tainly, patients should not be denied treatment. The access 
to objective information regarding stem cell treatment 
should be made widely available for all European citizens. 
Table 1
A glossary for stem cell biology. Adopted from EMBO Stem cell research: status, prospects, prerequisites 
and ref. 20.
Term Definition
Stem cell Cell that can continuously produce unaltered daughters and has the ability to produce daughter cells with different, more restricted, properties
Mesenchymal stem cell An adult multipotent cell derived from a well-characterized population that can form fat cells, carti-lage, bone, tendon and ligaments, muscle cells, skin cells and even nerve cells
Self-renewal Cycles of divisions which repeatedly generate at least one daughter equivalent to the mother cell with latent capacity for differentiation. The defining property of stem cells
Totipotent Self-sufficient to form an entire organism: capacity of zygote and of plant meristem cells, not demon-strated for any vertebrate stem cell
Pluripotent All cell lineages of the body including germ cells plus some or even all extraembryonic cell types; example: embryonic stem cells
Multipotent Multiple lineages that constitute an entire tissue or tissues; example: hematopoietic stem cells
Clonal analysis Investigation of properties of single cells. Essential for formal demonstration of self-renewal and potency
Embryonic stem cell Derived in vitro from pluripotent cells in the pre-gastrulation embryo
Tissue stem cell Derived from, or resident in, a fetal or adult tissue, with potency limited to cells of that tissue. Sus-tain turnover and repair throughout life in some tissue
Progenitor cells Generic term for any dividing cell with differentiation capacity. Includes putative stem cells in which self-renewal has not yet been demonstrated
Stem cell homeostasis Persistence of tissue stem cell pool throughout life. Requires balancing symmetric self-renewal and differentiated divisions at the population level, or sustained asymmetric self-renewal
Regenerative medicine Reconstruction of diseased or injured tissue by activation of endogenous cells or by cell transplantation
Cell replacement therapy Reconstruction of tissue by functional incorporation of transplanted stem cell progeny. Distinct from „bystander“ trophic, anti-inflammatory, or immunomodulatory effects of introduced cells
In vitro stem cells Self-renewal ex vivo in cells that do not overtly behave as stem cells in vivo. Occurs due to liberation from inductive commitment signals or by creation of a synthetic stem cell state 
Reprogramming Increase in potency. Occurs naturally in a regenerative organism („differentiation“). Induced experi-mentally in mammalian cells by nuclear transfer, cell fusion, or genetic manipulation
Plasticity Notion that tissue stem cells may broaden potency in response to physiological demands 
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Avoiding ethical (medical) tourism is extremely impor-
tant (5).
Naturally, investing into research brings substantial 
gains, as well as in the case of stem cell research. The 
National Institute of Health (NIH) has, in the period 
from 2005 to 2008, invested 3.5 billion $ for stem cell 
and regenerative medicine research, out of which 260 mil-
lion $ was invested into human stem cell research. This 
resulted in a turnabout in stem cell research; reprogram-
ming of adult stem cells into embryonic like stem cells, 
induced pluripotent stem cells (iPS). This discovery could 
not only push the boundaries of regenerative medicine, 
but could also solve all morally-ethical dilemmas over 
stem cell application (7).
In December 2008 the International Society for Stem 
Cell Research (ISSCR) has published „Guidelines for the 
clinical translation of stem cells“. The document is par-
tially supported by the EUROCORES programme 
EuroSTELLS, financed within the FP6 framework. This 
document served as a basis for the before mentioned NIH 
publication (5, 8).
AlternAtIve ApproAches to usIng 
stem cells
The term therapeutic cloning implies transfer of the so-
matic cell nucleus to an enucleated egg cell, followed by 
propagation of the hybrid cell to a cluster which is further 
directed towards development into specific tissue. This 
kind of therapy involves individually tailored embryonic 
stem cell therapy for cell or tissue replacement. In this 
manner, the problem of immunological compatibility is 
resolved, together with cell or tissue rejection, which is 
often the case with transplants (9).
Due to ethical problems connected with embryonic 
stem cells, adult stem cells were suggested as an alterna-
tive. They are multipotent, exist in many adult organs and 
can theoretically serve as a potential weapon for future 
therapy. Adult stem cells can be separated and, in some 
cases, ex vivo expanded. Furthermore, they can be trans-
planted back into the adult individual where they can 
differentiate and function normally. There are many 
known cases of successful conversion of adult stem cells, 
e.g. turning bone marrow cells into neurons or hepato-
cytes, liver stem cells into neurons or neurons into cardio-
myocytes. However, there are some problems related to 
adult stem cells. Their expansion is challenging since it is 
difficult to culture them in large numbers. Most likely 
they are not pluripotent and they are present in organs in 
low levels. Moreover, it is still not known whether they 
are affected by the process of aging. Finally, if the donor 
carries a certain genetic disease, adult stem cells may have 
the same genetic effect (6, 10, 11).
Another source for isolating progenitor cells without 
asking ethical questions connected with hESC research 
are amniotic stem cells. Amniotic fluid can serve as a new 
source for the isolation of cells with totipotent properties 
which can differentiate into various cell types. Amniotic 
stem cells could be used for the treatment of congenital 
defects, wherein only 2 ml of sample is needed to separate 
these cells in large enough numbers to construct material 
which contains fetal cells and could be used as an implan-
tation graft directly after birth.
Fetal cord blood stem cells can be used as another 
source for therapy. There are two types of such cells that 
are interested for therapeutic purposes: cord blood stem 
cells and fetal brain tissue. If treatments based on cord 
blood stem cells became available, the issue of social jus-
tice and social equality with regards to personal cord 
Table 2
Comparison between embryonic and adult stem cells. Adopted from EMBO Stem cell research: status, 
prospects, prerequisites.
Embryonic stem cells Adult stem cells
Are a ubiquitous component of the embryo with a  
well-understood function and life history
Are rare, often difficult to identify, of unknown origin, and partially 
understood function and life history
Are defined by position in the embryo (the inner cell mass of 
the blastocyst)
Are defined by a complex list of features such as cell-surface markers, 
behavior in vitro, and in some cases, position in the tissue
Can divide symmetrically indefinitely in culture without 
changing characteristics
Can divide few or many times (up to 200 or more) in culture, but 
not indefinitely
A single cell can give rise to a colony of genetically  
identical cells with the same properties as the original cell
In some tissues, absolutely consistent precursor cells can be  
identified and cultured; that remains to be shown for all tissues
Pluripotent: can give rise to all three tissue types of the em-
bryo (endoderm, mesoderm, ectoderm)
Sometimes multipotent: most only give rise to their tissue of origin, 
but some may be able to give rise to different cell types within the 
larger groupings of endoderm, mesoderm and ectoderm (so-called 
plasticity)
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blood banking would arise. Given that such banking is 
expensive, only a small proportion of the population may 
be able to buy access to a personal cord blood bank (5, 11, 
12). Fetal brain tissue from aborted fetuses has been used 
in the treatment of Parkinson’s disease.
In order to overcome possible ethical problems con-
nected with stem cells, in 2003 it was suggested that a 
stem cell bank should be formed. British Medical Re-
search Council funded this effort to store every kind of 
stem cell created in the UK, together with hundreds of 
others from different countries, with 9 billion pounds. 
The purpose is to supply researchers from all over the 
world with fetal, stem and adult stem cells (11). There is 
an increasing interest among private companies to create 
personal cell banks where parents can pay for their child’s 
umbilical cord to be stored for potential future therapeu-
tic use. It is far from clear whether treatments will be 
available based on stem cells derived from cord blood.
Shortage of egg cells is a setback for therapeutic clon-
ing. As a possible solution to this problem, fusing animal 
enucleated stem cell with human cell nucleus, thus creat-
ing chimeric embryos, was suggested. The newly formed 
cells have around 99,9% human genes and 0,1% genes of 
a cow or rabbit (oocyte mitochondrial genes). This proce-
dure was considered for the treatment of motor neuron 
diseases (turning stem cells into neurons) with an uncer-
tain final outcome (5, 13).
UK Parliament gave permission for the Human Fer-
tilization and Embryology Authority (HFEA) to create 
animal/human hybrid embryos using stem cell nuclear 
transfer. However, recent evidence suggests that animal/
human hybrids do not express the genes required for plu-
ripotency (14).
the morAl frAmework And the 
InItIAtIve for chArActerIzAtIon 
of stem cells
There are many issues that must be addressed concern-
ing the use of human stem cells for research and for clin-
ical application. Our moral framework is based on an 
imperative – to preserve and sustain life. The key question 
is whether it is permissible to prevent death and agony of 
children and adults by using cells separated from a fertil-
ized egg cell. How else can the legal approach to abortion 
or our readiness to remove ectopic pregnancy be ex-
plained? Human embryos have a limited potential to be-
come human beings. Most of them get lost before the 
menstrual period. Contraception methods that destroy 
embryos are used widely and there is a general public 
Table 3
Recommendations for the development of stem cell research.
In order for stem cell research and its development in Europe to have a chance of fulfilling its large potential for contribution to 
health, biological science and economy, several recommendations follow (5).
•  Prospective value of stem cell research for science, economy and medicine needs to be publicly recognized. Human stem cell 
research must enter the core of biomedical research, including disease modelling, research on cellular degenerative processes, the 
development of pharmaceutics, toxicological screening and regenerative therapy.
•  Adult and embryonic stem cell research, which is pronouncedly complementary, needs to fully be aided, which implies under-
standing the processes of reprogramming, nuclear transfer, cell fusion and other techniques.
•  Communication and professional education on stem cell research and its application must be promoted with active participation 
of scientists and clinicians together with ethicists and patient groups’ representatives. Intellectual ownership related to the usage 
of embryonic stem cells and cell lines after their derivation from embryos need to be patentable, in order to encourage industry 
participation in translational stem cell research in clinical application.
•  Stem cell research and application regulations should be clarified and harmonized, while legislative impediments for free scientific 
collaboration should be removed.
•  Regulative claims should not be too restrictive and they should not represent an unreasonable financial and bureaucratic obstacle 
for clinical application, as it is the case nowadays.
•  Efficient criterions and standard procedures for clinical use of stem cells must be developed. In an established clinical practice 
efficacy measures need to be at least at the level of the same measures for other safety controls.
•  Stem cell banks with high level of quality assurance, as well as international approach of scientists and industry, should be 
encouraged.
•  Greater harmonization and mutual interactions of clinical research and their results throughout Europe should be encouraged with 
transboundary studies and cell therapy evaluation. Such initiative should be aided by public financing and be of use to all citizens.
•  Technology development should be invested in to secure large scale processing of stem cells for applications in pharmaceutical 
screening, toxicological testing and cell transplantation.
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consent for in vitro fertilization (IVF); only 10% of trans-
ferred IVF embryos produce a baby, while 40 000 are 
generated through treatments in the UK and cannot be 
transferred.
Human embryonic stem cells are separated from the 
embryo in the early phase of its development. They can 
be isolated from inner cell mass as well as from morula, 
blastomere. These cells have the potential to develop into 
any cell or tissue and thus make for a potential source for 
transplantation and tissue engineering. First hESC lines 
were established in 1988 (15). Since then, and up to year 
2010, almost 700 cell lines were established in different 
countries. Legalization of usage of surplus egg cells made 
this possible. Many of these cell lines are registered in the 
European Human Embryonic Stem Cell Registry which 
is planned by the European commission. One of long 
term goals of the Human stem cell website is to establish 
a platform for comparing results of clinical research in 
Europe (12, 13).
One of laudable initiatives during the last years was the 
characterization of hESC lines. This project was led by 
International Stem Cell Forum (ICSF), an organization 
made of academies and research institute foundations 
from 21 member countries. The purpose of the project 
was to stimulate international collaboration and receive 
support for stem cell research. The initiative is known as 
Stem cell initiative 1 (ISCI 1). 58 hESC in 19 laboratories 
throughout the world were characterized. Results con-
firmed that those cell lines have similar expression profiles 
for several markers (15), although there are many differ-
ences between specific lines. The follow up ISCI 2 initia-
tive is examining conditions for growth and culturing of 
those cells, while ISCI 3 is examining hESC genetic sta-
bility, considering that those cells are going through ge-
netic alterations during long culturing (8).
clInIcAl ApplIcAtIon: problems 
And therApeutIc strAtegy
There are several possibilities of applying stem cells in 
regenerative medicine: researching fundamental aspects 
of stem cell biology, identifying new potential drugs, with 
the most important application being cell based therapy 
for injuries, diseases or disorders. European Tissue and 
Cell Directive (EUTCD) regulates the quality of cells 
used in human therapy and it demands good manufactur-
ing practice (GMP) for the production of those cells, 
which includes their quality. In relation to human stem 
cells, purity quality and product procedure is very strict. 
Difficulties arise when products contain animal compo-
nents such as mouse feeder cells or fetal bovine serum. 
Cells can absorb animal proteins which are immuno-
genic and can promote cell reactivity after transplanta-
tion. Such substances can contain infective agents which 
are difficult to remove after they had been exogenously 
imported. Hitherto, several hESC lines of special purity 
have been derived.
According to the current clinical status, hematopoi-
etic stem cells are often used for bone marrow transplan-
tation, while adult stem cells are still in the phase of early 
clinical evaluation. Web sites European Community Eu-
draCT (https://eudract.emea.europa.eu/) and US NIH 
(www.clinical trials.gov) give information over more than 
a hundred ongoing clinical tests based on usage of mes-
enchymal stem cells, a kind of adult stem cells which are 
soon expected to reach clinical use. Some of those trials 
are in phase III, therefore quite close to clinical exploita-
tion. Considerably more of such research is in phase I and 
II, and is conducted in Europe. Main foci of the ongoing 
research are steroid-refractory graft-versus-host disease, 
periodontitis, heavy chronic myocardial ischemia, distal 
tibia fracture, osteoarthritis, multiple sclerosis, vascular 
diseases, diabetes, decompensated liver cirrhosis, fistulis-
ing Chron disease, etc. (5).
Before the treatment has started, it is necessary to 
choose the cell type and preparative culture. Various stem 
cells have their own specificities and advantages, as well 
as faults related to regulation and mechanism of action. 
The most plausible and easiest option for implementation 
is the use of autologous stem cells, as they can be derived 
from adipose tissue or bone marrow. However, those cells 
can have a different tissue renewal capacity which can be 
caused by patient’s age, condition, nature of the disease, 
or a parallel medical treatment.
Another method of administrating autologous stem 
cells is generating iPS cells. There is, however, a potential 
risk of their inadequate „behavior“, such as tumor forma-
tion, which should be seriously investigated before this 
therapy truly enters clinic (7).
On the other hand, use of heterologous stem cells al-
lows for a logistically simplest method. Cells could be 
cultured and stored in banks, they could be significantly 
better characterized and even (genetically) modified be-
fore application. Yet, there is a risk of rejection (4, 5).
The choice of preparative cultivation of stem cells de-
pends on the suggested application and on the type of 
cells which are being used. If adult stem cells were used, 
long term cultivation would not be necessary, and cells 
could be prepared and selected in the operation hall. Such 
method would be simpler, since the risk of transformation 
during culturing would be reduced/eliminated. Cells 
could be registered as a medical device, and not as Ad-
vanced Therapy Medicinal Products (ATPM). Conflict-
ingly, if cultivation procedure would be utilized, a sig-
nificantly more extensive cell characterization could be 
carried out before the application itself. Considering the 
chosen options, therapeutic index clinical outcome (effi-
cacy/toxicity) would determine which approach is pre-
ferred in the specific clinical application.
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One of the current main questions which bothers sci-
entists working with human stem cells is therapy safety, 
including the question of epigenetic status and stability 
of cells. Thereat, the formation of teratoma after undif-
ferentiated hESC/iSP transplantation is a critical ques-
tion. Antiapoptotic gene surviving (15) plays a major role 
in the formation of tumorous tissue. This only illustrates 
the need for the development of efficient differentiation 
protocols based on generating fully differentiated and di-
rected precursor cells. Moreover, there are several strate-
gies available for avoiding undifferentiated hESC trans-
plantation, such as sorting pluripotent cells using 
GMP-grade flow cytometry or using suicidal genes.
What is the current situation in stem cell research in 
Europe? In the last decade, stem cell research in Europe 
has been very intense and has become globally competi-
tive. While media, on the one side, gave promises to the 
public, European scientists have seriously and responsibly 
approached the problem, making tremendous progress in 
fundamental research. With the advancement of research 
it became clear that tissue derived stem cells, hESC and 
iPS cells need to be studied in parallel. Well controlled 
clinical experiments were performed whenever it was con-
venient. With the growth of safety knowledge and differ-
ent cell type functions, that area will finally come closer 
to its expectations. Legislation on safe use of stem cells is 
successfully implemented, situation with research fund-
ing is improved, and some questions connected to pa-
tients, previously unanswered, are finally addressed. There 
is hope that treatments for many serious illnesses could 
be soon implemented. Stem cells offer the possibility for 
revolutionary therapy in medicine. That challenge needs 
to go hand in hand with the ethical principles based on a 
mutual EU concept, although they might differ from 
country to country (ESF Human Stem Cell Research and 
Regenerative Medicine: A European Perspective on Scien-
tific, Ethical and Legal Issue) (5, 16, 17, 18, 19).
In conclusion, any stem cell can be turned into any 
tissue given the appropriate conditions. More research has 
to be done before we understand whether there are restric-
tions on this process, whether it involves reprogramming 
that can lead to other unpredictable cellular behaviors 
and, finally, whether it even occurs at sufficiently high 
frequency to be clinically useful. Until then, there are no 
ethical and moral reasons to forbid embryonic stem cell 
therapeutic cloning.
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